NCT02495623View on ClinicalTrials.gov

A Study of the Effect of SYN-010 on Subjects With IBS-C

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

November 30, 2015

Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
DRUG

SYN-010 21 mg

DRUG

SYN-010 42 mg

DRUG

Placebo

Trial Locations (1)

Unknown

Miami

All Listed Sponsors
lead

Theriva Biologics, Inc.

INDUSTRY

NCT02495623 - A Study of the Effect of SYN-010 on Subjects With IBS-C | Biotech Hunter | Biotech Hunter